Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 août 2020 18h39 HE | Source: Bragar Eagel & Squire

PROTEOSTASIS THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PTI and Encourages Investors to Contact the Firm

NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
14 sept. 2016 16h03 HE | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Announces Closing of Follow-On Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused...
11 août 2016 07h45 HE | Source: Proteostasis Therapeutics, Inc

Proteostasis Therapeutics Issues Mid-Year Corporate Update on Cystic Fibrosis Pipeline Programs

CAMBRIDGE, Mass., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
30 mars 2016 14h07 HE | Source: Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential for Genotype-Agnostic and Combination Therapies for People with Cystic Fibrosis

CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
28 mars 2016 07h30 HE | Source: Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. Announces Scientific Presentations at 13th Annual European Cystic Fibrosis Society Basic Science Conference

CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...